Hosted on MSN19d
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The approval is backed by Amgen’s (AMGN) CodeBreaK 300 trial, in which patients on sotorasib 960 mg/panitumumab recorded over three months of median survival benefit without cancer progression ...
Nature1y
Trial shows the best way to treat colorectal cancer
The much-anticipated results of a trial of more than 800 participants in Japan revealed that, when coupled with standard chemotherapy, the drug panitumumab lowered the risk of death by 18% ...
ascopubs.org9d
Phase I/II study of cabozantinib alone or in combination with panitumumab in patients with MET-amplified metastatic colorectal cancer.
This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.
Pharmabiz17d
Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...